Mount Yale Investment Advisors LLC Sells 6,775 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mount Yale Investment Advisors LLC cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 56.7% during the 4th quarter, Holdings Channel reports. The fund owned 5,174 shares of the medical equipment provider’s stock after selling 6,775 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Hologic were worth $373,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. FMR LLC grew its stake in shares of Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after buying an additional 2,174,093 shares during the period. Nordea Investment Management AB raised its stake in Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after buying an additional 544,889 shares during the period. Swedbank AB boosted its holdings in Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after acquiring an additional 306,562 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after acquiring an additional 238,222 shares during the period. Finally, Barclays PLC increased its holdings in shares of Hologic by 47.6% during the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after acquiring an additional 231,578 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is owned by insiders.

Hologic Trading Down 0.5 %

Shares of HOLX stock opened at $71.41 on Thursday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a market cap of $16.12 billion, a P/E ratio of 21.44, a PEG ratio of 2.43 and a beta of 0.97. The company has a 50 day moving average of $73.62 and a 200-day moving average of $78.16. Hologic, Inc. has a 12-month low of $68.61 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.89 EPS. Sell-side analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Jefferies Financial Group began coverage on Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Royal Bank of Canada lifted their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Finally, UBS Group increased their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.